A practical reference on immunomodulator: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Moreover, a number of the key results in this field have shown that bioelectric circuits are non-local – regions of the body make decisions based on bioelectric events at a considerable distance. Such non-cell-autonomous events suggest distributed network models of bioelectric control; new computational and conceptual paradigms may need to be developed to understand spatial information processing in bioelectrically active tissues. It has been suggested that results from the fields of primitive cognition and unconventional computation are relevant to the program of cracking the bioelectric code. Finally, efforts in biomedicine and bioengineering are developing applications such as wearable bioreactors for delivering voltage-modifying reagents to wound sites, and ion channel-modifying drugs (a kind of electroceutical) for repair of birth defects and regenerative repair. Synthetic biologists are likewise starting to incorporate bioelectric circuits into hybrid constructs.
Bradykinin (BK) (from Greek brady- 'slow' + -kinin, kīn(eîn) 'to move') is a peptide that promotes inflammation. It causes arterioles to dilate (enlarge) via the release of prostacyclin, nitric oxide, and endothelium-derived hyperpolarizing factor, and induces smooth muscle constraction via prostaglandin F2. Bradykinin consists of nine amino acids, and is a physiologically and pharmacologically active peptide of the kinin group of proteins. A class of drugs called angiotensin-converting-enzyme inhibitors (ACE inhibitors) increase bradykinin levels by inhibiting its degradation, thereby increasing its blood pressure-lowering effect. ACE inhibitors are used to treat hypertension and heart failure.
==== Weight-related comorbidities ==== There are over 200 obesity-related comorbidities, and it has been reported that achieving a total body weight loss of 10% has a significant impact of such conditions. Thus, the weight loss outcomes with ESG are unsurprisingly accompanied by an improvement in several obesity-related comorbidities. Weight loss facilitated by ESG has been observed to bring about benefits in or even cure of diabetes/insulin sensitivity, dyslipidemia, blood pressure, and fatty liver disease, as well as quality of life. The MERIT study showed 80% of patients who underwent ESG had improvement in one or more comorbidities at one year.
Rotary ATPases F-ATPases (F1FO-ATPases) in mitochondria, chloroplasts and bacterial plasma membranes are the prime producers of ATP, using the proton gradient generated by oxidative phosphorylation (mitochondria) or photosynthesis (chloroplasts). F-ATPases lacking a delta/OSCP subunit move sodium ions instead. They are proposed to be called N-ATPases, since they seem to form a distinct group that is further apart from usual F-ATPases than A-ATPases are from V-ATPases. V-ATPases (V1VO-ATPases) are primarily found in eukaryotic vacuoles, catalysing ATP hydrolysis to transport solutes and lower pH in organelles like proton pump of lysosome. A-ATPases (A1AO-ATPases) are found in Archaea and some extremophilic bacteria. They are arranged like V-ATPases, but function like F-ATPases mainly as ATP synthases. Many homologs that are not necessarily rotaty exist. See ATP synthase § Evolution. P-ATPases (E1E2-ATPases) are found in bacteria, fungi and in eukaryotic plasma membranes and organelles, and function to transport a variety of different ions across membranes. E-ATPases are cell-surface enzymes that hydrolyze a range of NTPs, including extracellular ATP. Examples include ecto-ATPases, CD39s, and ecto-ATP/Dases, all of which are members of a "GDA1 CD39" superfamily. AAA proteins are a family of ring-shaped P-loop NTPases.
In early 1970, Parsons signed a solo deal with A&M Records and moved in with producer Terry Melcher. The two shared a penchant for cocaine and heroin, and the sessions were largely unproductive, with Parsons eventually losing interest in the project. The master tapes were lost; it is unclear who took them. Parsons accompanied the Rolling Stones on its 1971 UK tour in the hope of being signed to the newly formed Rolling Stones Records. He lived at Richards' French villa Nellcôte during the recording of Exile on Main Street, though he contributed little to the process. His drug use and constant quarrelling with his girlfriend, Gretchen Burrell, led to a request to leave by Richards' girlfriend, Anita Pallenberg. Parsons attempted to rekindle his relationship with the band on its 1972 American tour, to no avail. Parsons returned to the US for a one-off concert with the Burritos. In Washington, D.C., he met Emmylou Harris and asked her to join him in Los Angeles to record his first solo album. It came as a surprise to many when Parsons was signed to Reprise Records by Mo Ostin in mid-1972. The ensuing GP (1973) featured several members of Elvis Presley's TCB Band. It included six new songs from Parsons alongside several country covers, including Tompall Glaser's "Streets of Baltimore" and George Jones' "That's All It Took". Parsons, now featuring Harris as his duet partner, toured across the US as Gram Parsons and the Fallen Angels in February–March 1973.
Sources: en.wikipedia.org
Pakistan boasts literature in various languages including Urdu, Sindhi, Punjabi, Pashto, Baluchi, Persian, English, and more. The Pakistan Academy of Letters actively promotes literature and poetry both domestically and internationally. National Library contributes to literary dissemination. Historically, Pakistani literature consisted mainly of lyric, religious, and folkloric works, later diversifying under colonial influence into prose fiction, now widely embraced. The national poet of Pakistan, Muhammad Iqbal, wrote influential poetry in Urdu and Persian, advocating for Islamic civilisational revival. Notable figures in contemporary Urdu literature include Josh Malihabadi, Faiz Ahmed Faiz, and Saadat Hasan Manto. Popular Sufi poets like Shah Abdul Latif and Bulleh Shah are revered. Mirza Kalich Beg is hailed as the father of modern Sindhi prose. Pakistani philosophy has been shaped by influences from British and American philosophy, with notable figures like M. M. Sharif contributing to its development. After 1971, Marxist thought gained prominence in Pakistani philosophy through figures like Jalaludin Abdur Rahim.
Pharmacology is a branch of medical and biological sciences which encompasses the research, discovery, and characterization of chemicals exhibiting biological effects, alongside the elucidation of cellular and organismal function in relation to these chemicals. In contrast, pharmacy, a health services profession, is concerned with the application of the principles learned from pharmacology, pharmaceutics, medicinal chemistry, pharmacognosy, clinical pharmacy and others in its clinical settings; whether it be in a dispensing or clinical care role. In either field, the primary contrast between the two is their distinction between direct-patient care, pharmacy practice, and the science-oriented research field, inspired by pharmacology.
In a study with 17 volunteers, blood and saliva samples were collected before and at 15, 30, 60 and 240 min after ingesting 1 g of paracetamol. Detection from stimulated saliva and plasma with PA-MS provided a reliable result that can aid in making timely treatment decisions. Moreover, participants' views of blood and saliva sampling procedures were assessed qualitatively, showing a preference for non-invasive sampling.
Polydimethylsiloxane (PDMS) Poly(caprolactone (PCL) Poly(lactide) (PLA) Poly(methyl methacrylate) (PMMA) If enough of the block copolymer molecules that make up a polymersome are cross-linked, the polymersome can be made into a transportable powder. Polymersomes can be used to make an artificial cell if hemoglobin and other components are added. The first artificial cell was made by Thomas Chang.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.